Peripheral RIPK1 and IL-8 as Biomarkers in ALS: Evidence for Primidone Repurposing

Study Background and Research Question

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive degeneration of upper and lower motor neurons, leading to muscle weakness, atrophy, and ultimately respiratory failure. The majority of ALS cases are sporadic, with a smaller fraction linked to familial genetic variants. Despite advances in understanding the molecular underpinnings of ALS, effective disease-modifying therapies remain elusive. A growing body of research implicates receptor-interacting protein kinase 1 (RIPK1), a master regulator of apoptosis, necroptosis, and neuroinflammation, in the pathogenesis of ALS. However, translating RIPK1-targeted interventions into clinical benefit has been challenging, with previous clinical trials hampered by toxicity unrelated to target engagement. The study by Wei et al. (DOI: 10.1038/s41392-023-01713-z) addresses two critical questions: Are peripheral RIPK1 and IL-8 levels viable biomarkers of ALS disease activity? And can inhibition of RIPK1 via drug repurposing—specifically with Primidone (Mysoline)—offer a feasible therapeutic approach?

Key Innovation from the Reference Study

The central innovation of the Wei et al. study is twofold. First, it demonstrates that peripheral blood levels of RIPK1 and IL-8 are significantly elevated in ALS patients compared to healthy controls, with RIPK1 levels correlating with the severity of bulbar symptoms. Second, it provides the first clinical evidence that pharmacological inhibition of RIPK1 using Primidone—a well-characterized antiepileptic drug—results in marked reductions in these peripheral biomarkers. This dual advance positions RIPK1 and IL-8 not only as disease biomarkers but also as pharmacodynamic readouts for evaluating target engagement in ALS intervention studies (reference study).

Methods and Experimental Design Insights

Wei et al. employed a translational research strategy, bridging preclinical mouse models and human subjects. In the animal arm, SOD1^G93A transgenic mice—a widely used ALS model—were treated with Primidone to assess therapeutic efficacy and mechanistic effects. Disease onset, motor performance, and survival were tracked alongside serum biomarker analysis. In the clinical arm, 162 ALS patients received daily oral Primidone (62.5 mg) for 24 weeks, with serial measurements of serum RIPK1 and IL-8. Patient stratification included bulbar- and limb-onset ALS subtypes, allowing for correlation of biomarker levels with clinical severity. Notably, the study design incorporated both cross-sectional and longitudinal elements, supporting robust assessment of biomarker dynamics in relation to disease progression and intervention.

Protocol Parameters

• Primidone dosage in SOD1^G93A mice: Oral administration at 25 mg/kg/day enabled evaluation of both motor function and biomarker response in preclinical models.
• Human ALS cohort: Oral Primidone at 62.5 mg/day, with serum biomarker assessment at baseline and after 24 weeks of treatment.
• Biomarker endpoints: Quantification of serum RIPK1 and IL-8 using validated immunoassays, compared against healthy controls and correlated with disease metrics.

Core Findings and Why They Matter

Wei et al. found that ALS patients had significantly elevated serum RIPK1 and IL-8 compared to controls (P < 0.0001), supporting a relationship between systemic inflammation, cell death pathways, and ALS pathogenesis. Importantly, serum RIPK1 levels were positively correlated with the severity of bulbar symptoms (P < 0.05), suggesting a potential role as a surrogate marker for disease burden and progression. Following Primidone administration, both RIPK1 and IL-8 levels were substantially reduced, indicating effective central and peripheral pharmacological targeting of RIPK1 (reference study). In the SOD1^G93A mouse model, Primidone delayed symptomatic onset and improved motor performance, further validating the RIPK1 inhibition strategy in vivo. These findings establish not only the utility of peripheral RIPK1 and IL-8 as accessible biomarkers but also provide clinical proof-of-concept that repurposing Mysoline (Primidone) may offer therapeutic benefit in ALS—an area where few alternatives exist.

Comparison with Existing Internal Articles

The results of Wei et al. align with and extend prior discussions on the dual action of Primidone as both a RIPK1 and TRPM3 inhibitor. For instance, "Primidone (Mysoline): Mechanistic Insights and Translational Impact" explores the molecular basis for Primidone’s inhibition of RIPK1 and TRPM3, while "Primidone (Mysoline): Protocol Optimization for ALS & TRPM3 Assays" details dosing strategies and troubleshooting for both in vitro and in vivo ALS models. Both articles underscore the translational potential of Primidone in neurodegenerative research, reinforcing Wei et al.’s clinical observations. Additionally, internal summaries highlight that Primidone’s biomarker-lowering effects provide a direct pharmacodynamic link between intervention and central neuroinflammation, bridging the gap between preclinical studies and patient outcomes.

Limitations and Transferability

While the study makes a compelling case for Primidone’s repurposing, certain limitations must be acknowledged. First, although peripheral RIPK1 and IL-8 levels are promising biomarkers, their specificity to ALS versus other neuroinflammatory conditions remains to be fully characterized. The study’s 24-week follow-up, while adequate for biomarker assessment, does not fully address long-term clinical efficacy or safety of chronic Primidone administration in ALS patients. Additionally, the open-label design in the clinical arm may introduce bias, and further placebo-controlled studies are warranted. Finally, transferability to other neurodegenerative or inflammatory diseases, such as those involving TRPM3 channel dysfunction, remains a hypothesis for future research and should be approached cautiously until supported by targeted studies.

Research Support Resources

To facilitate replication and translational extension of these findings, researchers can access validated research-grade Primidone (SKU B2120) from APExBIO. This compound is characterized by its dual inhibition of RIPK1 kinase activity and TRPM3 ion channels, with recommended concentrations for cellular studies (0.1–1 μM for RIPK1 inhibition, 0.6–1.2 μM for TRPM3 inhibition) and established dosing protocols in ALS animal models. For detailed guidance on workflow optimization, see the internal protocol article "Primidone (Mysoline): Protocol Optimization for ALS & TRPM3 Assays". These resources support the rigorous implementation of RIPK1 and TRPM3 pathway studies in neurodegeneration and beyond.